-
Nov 13, 2024 | 
biorxiv.org | Pei Li |Julia Faraone |Michelle Chamblee |Yajie Liu
AbstractSARS-CoV-2 continues to evolve, producing new variants that drive global COVID-19 surges. XEC, a recombinant of KS.1.1 and KP.3.3, contains T22N and F59S mutations in the spike protein's N-terminal domain (NTD). The T22N mutation, similar to the DelS31 mutation in KP.3.1.1, introduces a potential N-linked glycosylation site in XEC.
-
Nov 6, 2024 | 
digitalcommons.library.tmc.edu | Panke Qu |Julia Faraone |John Evans |Yi-Min Zheng
Omicron subvariants continuingly challenge current vaccination strategies. Here, we demonstrate nearly complete escape of the XBB.1.5, CH.1.1, and CA.3.1 variants from neutralizing antibodies stimulated by three doses of mRNA vaccine or by BA.4/5 wave infection, but neutralization is rescued by a BA.5-containing bivalent booster. CH.1.1 and CA.3.1 show strong immune escape from monoclonal antibody S309.
-
Nov 6, 2024 | 
digitalcommons.library.tmc.edu | Panke Qu |Kai Xu |Julia Faraone |Negin Goodarzi
Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we characterized BA.2.86 and XBB-derived variant FLip by investigating their neutralization alongside D614G, BA.1, BA.2, BA.4/5, XBB.1.5, and EG.5.1 by sera from 3-dose-vaccinated and bivalent-vaccinated healthcare workers, XBB.1.5-wave-infected first responders, and monoclonal antibody (mAb) S309. We assessed the biology of the variant spikes by measuring viral infectivity and membrane fusogenicity.
-
Nov 6, 2024 | 
digitalcommons.library.tmc.edu | Panke Qu |John Evans |Julia Faraone |Yi-Min Zheng
AbstractThe continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron subvariants, including BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Here, we examine the neutralization resistance of these subvariants against sera from 3-dose vaccinated healthcare workers, hospitalized BA.1-wave patients, and BA.4/5-wave patients.
-
Nov 6, 2024 | 
digitalcommons.library.tmc.edu | Pei Li |Julia Faraone |Michelle Chamblee |Yi-Min Zheng
AbstractWe investigate JN.1-derived subvariants SLip, FLiRT, and KP.2 for neutralization by antibodies in vaccinated individuals, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients, or class III monoclonal antibody S309. Compared to JN.1, SLip, KP.2, and especially FLiRT exhibit increased resistance to bivalent-vaccinated and BA.2.86/JN.1-wave convalescent human sera.
-
Nov 6, 2024 | 
digitalcommons.library.tmc.edu | Julia Faraone |Panke Qu |Negin Goodarzi |Yi-Min Zheng
AbstractImmune evasion by SARS-CoV-2 paired with immune imprinting from monovalent mRNA vaccines has resulted in attenuated neutralizing antibody responses against Omicron subvariants. In this study, we characterized two new XBB variants rising in circulation - EG.5.1 and XBB.2.3, for their neutralization and syncytia formation. We determined the neutralizing antibody titers in sera of individuals that received a bivalent mRNA vaccine booster, BA.4/5-wave infection, or XBB.1.5-wave infection.
-
Sep 5, 2024 | 
biorxiv.org | Pei Li |Julia Faraone |Michelle Chamblee |Yajie Liu
AbstractDuring the summer of 2024, COVID-19 cases surged globally, driven by variants derived from JN.1 subvariants of SARS-CoV-2 that feature new mutations, particularly in the N-terminal domain (NTD) of the spike protein.
-
May 21, 2024 | 
biorxiv.org | Pei Li |Julia Faraone |Yi-Min Zheng |Michelle Chamblee
AbstractSARS-CoV-2 variants derived from the immune evasive JN.1 are on the rise worldwide. Here, we investigated JN.1-derived subvariants SLip, FLiRT, and KP.2 for their ability to be neutralized by antibodies in bivalent-vaccinated human sera, XBB.1.5 monovalent-vaccinated hamster sera, sera from people infected during the BA.2.86/JN.1 wave, and class III monoclonal antibody (Mab) S309.
-
Jan 8, 2024 | 01400-9&sz=64)
cell.com | Panke Qu |Kai Xu |Julia Faraone |Negin Goodarzi
Highlights•BA.2.86 is less immune evasive compared to FLip and other XBB variants•BA.2.86 is antigenically more similar to BA.2 and BA.4/5 than XBB variants•MAb S309 is unable to neutralize BA.2.86 possibly contributed by a D339H mutation•The fusion and infectivity of BA.2.86 is higher than XBB variants in CaLu-3 cellsSummaryEvolution of SARS-CoV-2 requires the reassessment of current vaccine measures.
-
Nov 21, 2023 | 00485-8&sz=64)
cell.com | Julia Faraone
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
